The stock of China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) increased by remained unchanged at $1.06, up 1.92 percent. The last five days have seen an average of 1,167,480 shares of common stock traded. 10 times new highs were reached in the current year, with a fall of -$0.2548. The average number of shares traded over the last 20 days was 368,300, while the average volume over the last 50 days totaled 243,842.
SXTC stock appreciated 0.95% since last month. On 10/06/21, the company’s shares reached a one-month low of $0.8900. The stock touched a high of $5.12 on 02/16/21, after rallying from a low of $0.89 in 52 weeks. The price of SXTC stock has declined by -19.38% or -$0.2548 this year, reaching a new high 10 times. Still, the stock price is down -79.30% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
The PE ratio of China SXT Pharmaceuticals Inc. has varied between 203.40 and 19.05 in the last five years. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 3.35, the price-to-book (PB) ratio of 1.03.
For the recent quarter, China SXT Pharmaceuticals Inc.’s quick ratio was 1.20, while its current ratio was 1.30, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 59.40% percent. China SXT Pharmaceuticals Inc.’s EBITDA margin for the recent year was -28.95%, whereas its operating margin stood at -45.50% for the same period. Based on annual data, it had gross profit of $2.84 million and revenue of $4.78 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. SXTC’s return on assets (ROA) during the last 12 months has been -10.60%. There was a -12.50% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -19.90%. ROE has averaged -15.50 in the past year for the broader industry.
At the end of China SXT Pharmaceuticals Inc.’s most recent quarter, its liabilities totaled 18.59 million, while its total debt was $12.71 million.
Here’s a quick look at China SXT Pharmaceuticals Inc.’s (SXTC) price momentum from a technical perspective. As of 22 October, the RSI 9-day stood at 60.55%, suggesting the stock is Neutral, with a 69.27% historical volatility rate.
The stochastic %K and %D were 55.17% and 47.59% respectively, while the average true range (ATR) was 0.0830. Based on the 14-day stochastic reading of 58.62%, the RSI (14) reading is 54.97%. On the 9-day MACD Oscillator, the stock is at 0.0568, and the 14-day reading is at 0.0766.
Analysts have assigned China SXT Pharmaceuticals Inc. (SXTC) an – rating. SXTC is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 0 others recommend it as a buy.